Psoriasis tends to look like a stubborn, slightly mysterious rash on the elbows and knees, and that is most of what gets flagged in a GP appointment. Underneath, it is an immune-driven systemic condition that runs in cycles for years, can worsen with infections and stress, and — particularly in school-age children and teenagers — carries a psychological weight that adults around them routinely underestimate. The plaques on a 12-year-old's scalp are not just a skin problem. They affect swimming, PE, school photographs, and a steady-state level of daily self-consciousness that accumulates.
Knowing what psoriasis is, what tends to set it off, and what treatments are now available — including modern biologics that have genuinely changed the picture for severe disease — lets you advocate for your child rather than feel along the surface of the problem.
Healthbooq covers chronic skin conditions in children. For the broader picture, see our complete guide to child health.
What Psoriasis Actually Is
Psoriasis is an autoimmune condition. T lymphocytes drive an inflammatory loop that pushes skin cell turnover into overdrive — cells that normally take around 28 days to mature and shed are replaced in 3–7 days in psoriatic skin. The pile-up of immature cells creates the characteristic plaque: a raised, well-demarcated patch of red skin with a silvery white scale on top.
It is a chronic, relapsing condition: long stretches of relative quiet punctuated by flares, often triggered by something identifiable (an infection, a stress, an injury). The genetic basis is real — about a third of people with psoriasis have a first-degree relative with the condition, and the strongest single susceptibility marker is HLA-Cw6. It is not contagious, which is worth saying out loud to children who are old enough to worry that other children think it is.
The Patterns That Show Up in Children
Plaque psoriasis is the most common type at any age. In children, the typical sites are elbows, knees, lower back, and scalp. The plaques are well-defined, raised, red, and topped with silvery scale. Nails can be affected — pitting, onycholysis (separation of the nail from the bed), the "oil drop" sign — and while nail involvement is less common in children than in adults, it does occur and is worth pointing out at consultations because it changes the picture clinically.
Guttate psoriasis is particularly common in children and teenagers. It looks completely different from plaque disease: hundreds of small (0.5–1.5 cm) pink, teardrop-shaped spots scattered across the trunk and limbs, often appearing two to three weeks after a streptococcal throat infection. The link with Group A Streptococcus is well established (Reynolds and colleagues among others). Guttate psoriasis often settles spontaneously over weeks to a few months and may not return — but a meaningful proportion of children with guttate disease go on to develop chronic plaque psoriasis later, which is why follow-up matters.
Scalp psoriasis is common, often distressing, and frequently mistaken for severe dandruff. Plaques can extend beyond the hairline onto the forehead or behind the ears. For a child or teenager, visible flaking on dark school uniforms is one of the more common reasons treatment becomes a priority.
Flexural (inverse) psoriasis appears in the skin folds — nappy area in babies, armpits, groin, under the breasts in older children. Because of the moist environment, the typical silvery scale is absent and the lesions look smooth, glossy, and red. This pattern is easily mistaken for fungal infection or simple nappy rash; if a "nappy rash" is not responding to standard treatment, psoriasis is on the differential.
What Sets It Off
The most important trigger in children, by some distance, is streptococcal throat infection — particularly for guttate flares. Other identified triggers:
- Stress. Real, repeated, and often visible in the timeline of flares.
- Skin injury — the Koebner phenomenon, where psoriasis appears at sites of trauma (a scratch, a sunburn, a tattoo).
- Certain medications: beta-blockers, lithium, NSAIDs, and occasionally antimalarials can flare psoriasis. Worth flagging if a child with known psoriasis is starting one of these.
- Obesity. Increasingly recognised as a risk factor for more severe psoriasis in adolescents, with biologically plausible inflammatory mechanisms.
- Smoking and alcohol worsen psoriasis in older teenagers.
For a child who flares with throat infections, prompt assessment and treatment of strep throat is one of the more useful preventive measures.
How Treatment Is Stepped
The stepwise approach in NICE NG6 is the framework UK paediatric dermatology services follow.
Topical treatments are first-line for almost all children. A few principles:
- Emollients are daily, flare or no flare. They reduce scaling and dryness and are the foundation everything else sits on. A generous tub of an unfragranced emollient applied at least twice a day is non-negotiable.
- Topical corticosteroids address inflammation during flares. Potency is calibrated to site: mild (1% hydrocortisone) for the face and flexures, moderate to potent for the body and scalp, used intermittently — typically two to four weeks of active treatment then a break — to limit side effects (skin thinning, telangiectasia, rebound flare on rapid withdrawal).
- Vitamin D analogues (calcipotriol) work via a different mechanism and pair well with steroids; the combination product Dovobet (calcipotriol plus betamethasone) is widely used.
- Coal tar preparations remain useful, particularly for the scalp. They are smelly and stain, which is why teenagers tolerate them less well; modern formulations are better.
Phototherapy (narrow-band UVB) is the next step for widespread or moderate disease that has not responded to topicals. It requires regular clinic attendance — typically two to three times weekly for several weeks — which is not always practical for school-age children.
Systemic treatments for moderate-to-severe disease include methotrexate (most commonly used in children), ciclosporin (short-term only because of nephrotoxicity), and acitretin (a retinoid that is not appropriate for girls of childbearing potential because of teratogenicity).
Biologics have transformed the prognosis for severe paediatric psoriasis over the last decade. The current UK paediatric licensed agents:
- Adalimumab (anti-TNF) — licensed from age 4 for severe chronic plaque psoriasis.
- Secukinumab (anti-IL-17A) — licensed from age 6.
- Ixekizumab (anti-IL-17A) — licensed from age 6.
These produce clear or almost-clear skin in the majority of children with severe disease, with side-effect profiles that are well characterised and broadly acceptable. NICE NG6 sets out when biologics should be considered. If a child has severe disease that has failed conventional therapies, a paediatric dermatology referral and a discussion about biologics is the appropriate next step.
The Psychological Side That Gets Missed
Studies using the Children's Dermatology Life Quality Index (CDLQI) consistently find that psoriasis affects daily life as much as — and sometimes more than — conditions like type 1 diabetes that everyone takes seriously. Children with psoriasis have measurably higher rates of anxiety, depression, peer difficulties, and self-consciousness about appearance. The 13-year-old refusing to go swimming, the 9-year-old who has stopped putting their hand up in class because the plaques on their forearm are visible, the teenager spending an hour each morning trying to comb scale out of their hair — these are clinical issues, not personality issues.
Psychological support should be a routine part of moderate-to-severe psoriasis care, not something offered when a child is already in crisis. Many paediatric dermatology services have a clinical psychologist embedded in the team, and asking about this at the first specialist appointment is reasonable. Charities like the Psoriasis Association (psoriasis-association.org.uk) provide age-appropriate resources for children and teenagers and a helpline for parents.
A child or teenager living with psoriasis is not "just" managing a skin condition. They are managing the visibility of a skin condition through years of social development, and the treatment plan is more likely to work when that side of it is taken seriously from the start.
Key Takeaways
Psoriasis is a chronic immune-driven skin condition that affects 1–2% of the UK population, with about one-third of cases starting in childhood. Children most commonly present with plaque psoriasis (red plaques with silvery scale on elbows, knees, scalp) or guttate psoriasis (showers of small teardrop spots, classically two to three weeks after a streptococcal throat infection). Treatment is stepped: emollients and topical steroids first, vitamin D analogues alongside, phototherapy or systemic agents for moderate disease, and modern biologics — adalimumab from age 4, secukinumab and ixekizumab from age 6 — that have transformed outcomes for severe paediatric psoriasis. NICE NG6 is the UK reference. The psychological burden is consistently underestimated and deserves explicit attention as part of care, not an afterthought.
